{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:07:30Z","timestamp":1791310050170,"version":"4.3.1"},"update-to":[{"DOI":"10.1002\/14651858.cd001417.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,2,25]],"date-time":"2014-02-25T00:00:00Z","timestamp":1393286400000}}],"reference-count":42,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd001417.pub3","type":"journal-article","created":{"date-parts":[[2014,2,25]],"date-time":"2014-02-25T20:06:15Z","timestamp":1393358775000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Topiramate add-on for drug-resistant partial epilepsy"],"prefix":"10.1002","author":[{"given":"Jennifer","family":"Pulman","sequence":"first","affiliation":[{"name":"Institute of Translational Medicine, University of Liverpool; Department of Molecular and Clinical Pharmacology; Clinical Sciences Centre for Research and Education, Lower Lane Fazakerley Liverpool Merseyside UK L9 7LJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Jette","sequence":"additional","affiliation":[{"name":"University of Calgary, Foothills Medical Centre; Department of Clinical Neurosciences and Hotchkiss Brain Institute\/Department of Community Health Sciences and Institute for Public Health; 1403-29 Street NW Calgary, Alberta Canada TN2 2T9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Dykeman","sequence":"additional","affiliation":[{"name":"University of Calgary; Department of Clinical Neurosciences\/Community Health Sciences; 1403 29 Street NW Calgary Alberta Canada T2N 2T9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla","family":"Hemming","sequence":"additional","affiliation":[{"name":"University of Birmingham; Public Health, Epidemiology and Biostatistics; Edgbaston Birmingham UK B15 2TT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane L","family":"Hutton","sequence":"additional","affiliation":[{"name":"University of Warwick; Department of Statistics; Coventry UK CV4 7AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony G","family":"Marson","sequence":"additional","affiliation":[{"name":"Institute of Translational Medicine, University of Liverpool; Department of Molecular and Clinical Pharmacology; Clinical Sciences Centre for Research and Education, Lower Lane Fazakerley Liverpool Merseyside UK L9 7LJ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,2,25]]},"reference":[{"key":"10.1002\/14651858.CD001417.pub3-BIB0001|cit1","first-page":"S150","article-title":"Double-blind, placebo-controlled trial of 800 mg\/day topiramate as add-on therapy in patients with refractory partial epilepsy","volume":"36","author":"Ben-Menachem","year":"1995","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001417.pub3-BIB0002|cit2","first-page":"109","article-title":"Topiramate add-on treatment in patients with intractable partial epilepsy: a multicenter study","volume":"34","author":"Ben-Menachem","year":"1993","journal-title":"Epilepsia"},{"issue":"6","key":"10.1002\/14651858.CD001417.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1528-1157.1996.tb00606.x","article-title":"Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures","volume":"37","author":"Ben-Menachem","year":"1996","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001417.pub3-BIB0004|cit4","first-page":"S149","article-title":"Double-blind, placebo-controlled trial of 400 mg\/day topiramate as add-on therapy in patients with refractory partial epilepsy","volume":"36","author":"Martinez-Lage","year":"1995","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001417.pub3-BIB0005|cit5","first-page":"105","article-title":"Topiramate as add-on therapy in refractory partial epilepsy","volume":"33","author":"Ostergard","year":"1992","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001417.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1212\/WNL.52.7.1338","article-title":"A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children","volume":"52","author":"Elterman","year":"1999","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001417.pub3-BIB0008|cit7","first-page":"33","article-title":"Topiramate dose-ranging trial in refractory partial epilepsy","volume":"36","author":"Faught","year":"1995","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001417.pub3-BIB0007|cit8","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1212\/WNL.46.6.1684","article-title":"Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages","volume":"46","author":"Faught","year":"1996","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001417.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1034\/j.1600-0404.2002.02071.x","article-title":"Low-dose topiramate in adults with treatment-resistant partial-onset seizures","volume":"106","author":"Guberman","year":"2002","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1002\/14651858.CD001417.pub3-BIB0010|cit10","first-page":"179","article-title":"Efficacy of 200 mg\/day topiramate in treatment-resistant partial seizures when added to an enzyme-inducing anti-epileptic drug (AED)","volume":"42","author":"Guberman","year":"2001","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001417.pub3-BIB0011|cit11","first-page":"35","article-title":"Efficacy and tolerability of 200 mg\/day topiramate in a placebo-controlled comparison of titration rates","volume":"41","author":"Neto","year":"2000","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001417.pub3-BIB0012|cit12","first-page":"152","article-title":"Weight reduction during topiramate treatment of partial seizures","volume":"43","author":"Oene","year":"2002","journal-title":"Epilepsia"},{"issue":"12","key":"10.1002\/14651858.CD001417.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1111\/j.1528-1157.1999.tb01596.x","article-title":"Topiramate in medically intractable partial epilepsies: double-blind placebo-controlled randomized parallel group trial","volume":"40","author":"Korean Topiramate Study Group","year":"1999","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001417.pub3-BIB0014|cit14","first-page":"809","article-title":"Double-blind placebo-controlled randomized clinical trial of topiramate add-on therapy in medically intractable partial epilepsies","volume":"16","author":"Lee","year":"1998","journal-title":"Journal of the Korean Neurology Association"},{"key":"10.1002\/14651858.CD001417.pub3-BIB0015|cit15","first-page":"33","article-title":"Dose-ranging trial with higher doses of topiramate in patients with resistant partial seizures","volume":"36","author":"Privitera","year":"1995","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001417.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1212\/WNL.46.6.1678","article-title":"Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages","volume":"46","author":"Privitera","year":"1996","journal-title":"Neurology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD001417.pub3-BIB0017|cit17","first-page":"153","article-title":"Placebo-controlled trial of topiramate as adjunctive therapy to carbamazepine or phenytoin for partial-onset seizures","volume":"37","author":"Rosenfeld","year":"1996","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001417.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0920-1211(96)00029-0","article-title":"Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy","volume":"25","author":"Sharief","year":"1996","journal-title":"Epilepsy Research"},{"key":"10.1002\/14651858.CD001417.pub3-BIB0019|cit19","first-page":"41","article-title":"Adjuvant topiramate treatment in intractable partial epilepsy","volume":"6","author":"Sharief","year":"1993","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001417.pub3-BIB0020|cit20","first-page":"S150","article-title":"Double-blind, placebo-controlled trial of 600 mg\/day topiramate as add-on therapy in patients with refractory partial epilepsy","volume":"Suppl 3","author":"Tassinari","year":"1995","journal-title":"Epilepsia"},{"issue":"8","key":"10.1002\/14651858.CD001417.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1528-1157.1996.tb00649.x","article-title":"Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy","volume":"37","author":"Tassinari","year":"1996","journal-title":"Epilepsia"},{"issue":"9","key":"10.1002\/14651858.CD001417.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1528-1157.2000.tb00321.x","article-title":"A double-blind, placebo-controlled study of topiramate in adult patients with refractory partial epilepsy","volume":"41","author":"Yen","year":"2000","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001417.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1177\/147323001103900208","article-title":"Topiramate as an adjunctive treatment for refractory partial epilepsy in the elderly","volume":"39","author":"Zhang","year":"2011","journal-title":"Journal of International Medical Research"},{"key":"10.1002\/14651858.CD001417.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1212\/01.WNL.0000091867.09720.6B","article-title":"Randomized, concentration-controlled trail of topiramate in refractory focal epilepsy","volume":"61","author":"Christensen","year":"2003","journal-title":"Neurology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD001417.pub3-BIB0025|cit25","first-page":"285","article-title":"Seizure severity in patients with partial onset (POS) or primary generalised tonic-clonic (PGTC) seizures following treatment with topiramate. A comparison of two different methodologies in a randomised controlled trial","volume":"40","author":"Coles","year":"1999","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001417.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1212\/WNL.0b013e3181d1cd4c","article-title":"Randomized trial of adjunctive topiramate therapy in infants with refractory partial seizures","volume":"74","author":"Novotny","year":"2010","journal-title":"Neurology"},{"issue":"7","key":"10.1002\/14651858.CD001417.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/j.1528-1167.2008.01584.x","article-title":"Topiramate in older patients with partial-onset seizures: a pilot double-blind, dose-comparison study","volume":"49","author":"Ramsay","year":"2008","journal-title":"Epilepsia"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD001417.pub3-BIB0028|cit28","first-page":"11","article-title":"Safety and effectiveness of three oral doses of topiramate in the treatment of patients with refractory partial epilepsy","volume":"32","author":"Aranguiz","year":"1991","journal-title":"Epilepsia"},{"issue":"Suppl","key":"10.1002\/14651858.CD001417.pub3-BIB0029|cit29","first-page":"38","article-title":"Efficacy of therapy with new antiepileptic drugs (tiagabine, gabapentin, topiramate) in drug-resistant epilepsy","volume":"41","author":"Kazibutowska","year":"2000","journal-title":"Epilepsia"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD001417.pub3-BIB0030|cit30","first-page":"114","article-title":"Topiramate (TPM) in older adults with partial-onset seizures: a double-blind, dose-comparison study","volume":"46","author":"Ramsay","year":"2005","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001417.pub3-BIB0031|cit31","unstructured":"Brown SD Wolf HH Swinyard EA The novel anticonvulsant topiramate enhances GABA-mediated chloride flux Epilepsia 1993 122"},{"key":"10.1002\/14651858.CD001417.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0140-6736(95)91208-8","article-title":"Remission of epilepsy: results from the national general practice study of epilepsy","volume":"346","author":"Cockerell","year":"1995","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD001417.pub3-BIB0033|cit33","first-page":"123","article-title":"Selective effects of topiramate on sustained repetitive firing and spontaneous bursting in cultured hippocampal neurons","volume":"34","author":"Coulter","year":"1993","journal-title":"Epilepsia"},{"issue":"4","key":"10.1002\/14651858.CD001417.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1468-1331.2004.00992.x","article-title":"The epidemiology of epilepsy in Europe - a systematic review","volume":"12","author":"Forsgren","year":"2005","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD001417.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1528-1157.1975.tb04721.x","article-title":"The epidemiology of epilepsy in Rochester, Minnesota, 1935 through 1967","volume":"16","author":"Hauser","year":"1975","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001417.pub3-BIB0036|cit36","unstructured":"Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD001417.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/bmj.c365","article-title":"The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews","volume":"340","author":"Kirkham","year":"2010","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD001417.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD001417.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1528-1157.1981.tb06158.x","article-title":"Phenytoin for epilepsy: a long term prospective study, assisted by serum level monitoring in previously untreated patients","volume":"22","author":"Reynolds","year":"1981","journal-title":"Epilepsia"},{"issue":"3","key":"10.1002\/14651858.CD001417.pub3-BIB0040|cit40","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001417.pub2","article-title":"Topiramate add-on for drug-resistant partial epilepsy","author":"Jette","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD001417.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1136\/bmj.313.7066.1169","article-title":"New antiepileptic drugs; a systematic review of their efficacy and tolerability","volume":"313","author":"Marson","year":"1996","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD001417.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1528-1157.1997.tb01251.x","article-title":"The new antiepileptic drugs; a systematic review of their efficacy and tolerability","volume":"38","author":"Marson","year":"1997","journal-title":"Epilepsia"}],"updated-by":[{"DOI":"10.1002\/14651858.cd001417.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T00:00:00Z","timestamp":1571788800000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD001417.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T21:02:48Z","timestamp":1628542968000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD001417.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Epilepsy Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,2,25]]},"references-count":42,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001417.pub3","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD001417.pub4","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,25]]}}}